Makes synthetic genes for biotech and pharma companies to develop therapeutics.
Jun 2026Revenue $432M/yrExpenses $577M/yr
Expected break-even May 2033Cash runway ≈ 1.8 years from Jun 2026
Figures by year
When will Twist Bioscience be profitable?
Its revenue and expense trends are projected to cross in May 2033. In the 12 months to Jun 2026, revenue was $432M and expenses $577M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2025 | $377M | $513M | −$136M |
| Sep 2024 | $313M | $534M | −$221M |
| Sep 2023 | $245M | $462M | −$217M |
| Sep 2022 | $204M | $438M | −$235M |
| Sep 2021 | $132M | $285M | −$153M |
| Sep 2020 | $90.1M | $230M | −$140M |
| Sep 2019 | $54.4M | $163M | −$109M |
| Sep 2018 | $25.4M | $96.0M | −$70.6M |
| Sep 2017 | $10.8M | $69.2M | −$58.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.